Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)

• Company Description    Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $8.52 Daily Weekly Monthly 20 Day Moving Average: 2,087,930 shares Shares Outstanding: 54.41 (millions) Market Capitalization: $463.58 (millions) Beta: 0.09 52 Week High: $12.14 52 Week Low: $1.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.35% -12.99% 12 Week -4.59% -7.20% Year To Date 62.91% 55.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11400 WEST OLYMPIC BLVD SUITE 200 - LOS ANGELES,CA 90064 USA ph: 310-651-8041 fax: - None http://www.immixbio.com

• General Corporate Information    Officers Ilya Rachman - Chief Executive Officer Gabriel Morris - Chief Financial Officer; President and Director Jason Hsu - Director Magda Marquet - Director Helen C. Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258H106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 54.41 Most Recent Split Date: (:1) Beta: 0.09 Market Capitalization: $463.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 6.82% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: 35.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -73.24 12/31/25 - -101.25 ROA 06/30/26 - - 03/31/26 - -59.20 12/31/25 - -73.39 Current Ratio 06/30/26 - - 03/31/26 - 8.75 12/31/25 - 10.01 Quick Ratio 06/30/26 - - 03/31/26 - 8.75 12/31/25 - 10.01 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.59 12/31/25 - 1.77 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©